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Research on oncogenic infectious agents� espe-
cially viruses� has helped us to understand the process 
of malignant transformation of cells �ecause the cel-
lular events in viral-driven transformation mirror� often 
�rilliantly� �asic cellular processes that culminate 
in cancer� even those not associated with viruses. In-
fectious agents� especially viruses� account for several 
of the most common malignancies — up to ��% of all 
cancers. Some of these cancers are endemic� with 
a high incidence in certain geographic locations� �ut 
sporadic/lower incidence in other parts of the world. 
Lymphomas arise frequently in association with viruses 
such as Epstein-Barr virus� human herpesvirus � �HHV-
��� human immunodeficiency virus �HIV�� human T-
lymphotropic virus-� �HTLV-��� and hepatitis C virus 
�HCV�. Viruses may contri�ute to lymphomagenesis 
either �y directly infecting the tumor clone �e.g. EBV� 
HHV�� HTLV-��� or via indirect mechanisms altering 
the host immunity �e.g. HIV� or microenvironmental 
interactions �e.g. HCV�.
Gamma-herpesviruses. Two lymphotropic hu-
man gamma herpesviruses can cause� or predispose 
to� lymphoproliferative disorders: Epstein — Barr virus 
�EBV� formally designated as human herpesvirus �� 
and Kaposi sarcoma herpesvirus �KSHV� also called 
human herpesvirus ��. Individuals with inherited or ac-
quired immunodeficiency have a greatly increased risk 
of developing a malignancy caused �y one of these 
two viruses. Specific types of EBV- or HHV-� related 
lymphomas occur predominantly or almost exclusively 
in individuals with HIV infection� transplant recipients 
and children with primary immunodeficiency. Some 
of these diseases� such as Hodgkin and non-Hodgkin 
lymphoma resem�le those occurring in immunocom-
petent patients� �ut the proportion of tumors in which 
EBV is present is increased. Others� like primary ef-
fusion lymphoma and polymorphic post-transplant 
lymphoproliferative disorders� are rarely seen outside 
the context of a specific immunodeficient state.
HIV. The clinical features and natural history of HIV-
associated lymphomas differ greatly from those o�-
served in the general population. The failure to improve 
outcomes with treatment intensification indicates the 
need for the introduction of new therapeutic options. 
HIV-associated lymphomas still represent a relevant 
field of clinical research. Standard methodologies for 
therapy in this patient population have yet to �e esta�-
lished. However� rituxima� plus chemotherapy should 
�e offered to the majority of patients with HIV infection 
and diffuse large B-cell lymphoma and the feasi�ility 
of intensive aggressive chemotherapy regimens has 
�een successfully tested in HIV-associated Burkitt 
lymphomas.
HTLV-I. Adult T-cell leukemia-lymphoma �ATLL� 
is a peripheral T-cell malignancy� closely associated 
with HTLV-� infection. Clinically� ATLL is classified into 
four su�types: acute� lymphoma� chronic and smol-
dering type. Although the prognosis of chronic and 
smoldering-type ATLL is relatively good� that of pa-
tients with acute- or lymphoma-type ATLL still remains 
extremely poor. Zidovudine/IFN-a therapy seems 
to �e promising� although its efficacy has not yet �een 
confirmed in well-designed prospective studies. High-
dose chemotherapy with the support of autologous 
transplantation does not improve outcome. Allogeneic 
stem cell transplantation is promising and approxi-
mately ��% of aggressive ATLL patients are expected 
to survive long-term� although transplantation-related 
mortality is as high as ���5�%.
HCV. HCV is well known for its aetiological role 
in chronic non-A� non-B viral hepatitis� liver cirrhosis 
and hepatocellular carcinoma; in addition� the virus 
has also �een implicated in a num�er of extra-hepatic 
“autoimmune” disease manifestations. A causative 
association �etween HCV and non-Hodgkin lym-
phoma �NHL� was postulated relatively recently and 
has �een the su�ject of intense investigation� as well 
as some de�ate. On the strength of epidemiological 
data� emerging �iological investigations and clini-
cal o�servations� HCV appears to �e involved in the 
pathogenesis of at least a proportion of patients with 
NHL. Morphologically� HCV-associated lymphomas 
represent a variety of histological su�types including 
marginal zone lymphoma �splenic� nodal and extrano-
dal�� small lymphocytic lymphoma/chronic lympho-
cytic leukaemia� lymphoplasmacytic lymphoma and 
diffuse large B-cell lymphoma. Remarka�ly� some 
HCV-associated NHL appear to �e highly responsive 
to antiviral therapy� providing some clinical evidence 
for this relationship� as well as the prospect for novel 
therapeutic intervention.
Perspectives. Some virus-related lymphomas 
may �e difficult to treat with conventional approaches. 
�espite recent advancements using cytotoxic� lym-
phoma-specific� and adoptive therapies� the long-term 
outcome of patients with y-herpesvirus lymphomas 
occurring in severely immunocompromised patients 
and ATLL continues to �e poor. Lytic-inducing thera-
pies targeting NF-kB, and viral and tumor cell epigen-
etic mechanisms afford the advantage of exploiting the 
intrinsic presence of oncogenic viruses to eradicate 
infected tumor cells. On these grounds� novel clinical 
approaches targeting viral latency are currently �eing 
investigated.
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B-cell non-Hodgkin lymphomas �NHL� mostly pres-
ent as disseminated diseases involving lymph nodes� 
spleen and liver and often the �one marrow �BM�. 
Tumor cells can also �e found in the �lood �leukemic 
disease�� especially in the indolent lymphomas. High 
white �lood cell counts and a differential demonstra-
ting a lymphocytosis in the �lood require immunophe-
notyping for characterization of the leukemic cells. 
Molecular/cytogenetic analyses may also have a role 
in the diagnostic classification of the disease. Besides 
the specific diagnosis� the clinical evaluation of the pa-
tient and prognostic markers are of most importance 
for selecting the �est type of therapy.
Follicular lymphoma (FL) is the indolent lymphoma 
with the highest incidence. Most patients present 
with advanced stage disease with BM involvement 
in �����% of the cases� and few are leukemic at the 
time of diagnosis. By high-resolution analysis circulating 
FL cells may �e detected in more patients. Leukemic pa-
tients mostly have concomitant lymph node involvement 
and high tumor �urden. A pure FL-cell leukemia with 
C���+C���+C�5� clonal cells has also �een descri�ed� 
mostly associated with an indolent clinical outcome. 
FL carry a t�l�;l���q��;q�l� translocation in more than 
9�% of cases� juxtaposing the immunoglo�ulin heavy 
chain �IGH� �’ Regulatory Regions �lgH-�’RR� to the 
BCL2 gene� resulting in overexpression of the Bcl� anti-
apoptotic protein. FL cells are also dependent on signals 
from the microenvironment to survive and proliferate. 
Several groups� including ours� have reported that 
immune cells in the lymphoma microenvironment and 
in �lood influence prognosis. In patients treated �efore 
the introduction of rituxima�� we have found that a high 
num�er of P�-�+� FOXP�+ and C��+ T-cell su�sets in the 
tumor microenvironment predict superior outcome� 
while C��+ follicular helper T cells and C�6�+ macro-
phages are associated with an inferior outcome. The 
introduction of the anti-C��� anti�ody rituxima� has 
improved the prognosis for FL patients. The efficacy 
of this drug is excellent also as monotherapy especially 
in patients with high num�ers of C��+ T-cells in the 
lymph nodes as well as in the �lood.
Mantle cell lymphoma (MCL): MCL cells carries 
the t�l �:��� translocation resulting in enhanced cyclin 
�l expression and cyclin �I-dependent kinase activ-
ity� promoting cell cycle progression. Immunological 
markers show a typical phenotype �C���+C�5+C������ 
�ut also atypical phenotypes �C���+C�5�C���� 
or C���+C�5+C���+� in some cases. Most MCL patients 
have an unfavora�le prognosis and intensive treatment 
strategies are required. However� in around ��% of the 
patients the disease shows an indolent clinical course 
with often a non-nodal� leukemic disease. In one study 
the clinicopathologic features� gene expression and 
genomic profiles were compared in patients with in-
dolent �iMCL� and in those with conventional disease 
�cMCL�. iMCL and cMCL shared a common gene 
expression profile that differed from other leukemic 
lymphoid neoplasms and a signature of �� genes was 
underexpressed in iMCL� among these SOXI1. The SOX 
I1-negative tumors exhi�ited more frequent non-nodal 
presentation and �etter survival compared with SOX 
I1-positive MCL. Recently� our group found that SOXII-
negative MCL had a higher frequency of lymphocytosis� 
�ut also elevated L�H and p5� positivity. Moreover� 
SOXII- negative cases had a shorter overall survival than 
SOXII-positive cases. �ue to the conflicting results� the 
conclusion is that SOXII cannot �e used for predicting 
an indolent disease course. In another study� deletions 
at ��p�� (TP53) and ��q�� were frequent in leukemic 
MCL and involved the majority of the leukemic clone. 
Cases with TP53 deletion were more likely to have 
splenomegaly and marked leucocytosis �> �� × ��9/L�� 
and were less likely to have lymphadenopathy than 
those without the deletion. Other distinctive �iological 
features in non-nodal leukemic MCL are mutated IGHV 
and a transcriptional profile lacking tumor invasion prop-
erties� which might contri�ute to the a�sence of nodal 
involvement. In conclusion� MCL patients with leukemic 
disease �ut without clinical symptoms might �e man-
aged conservatively with a “wait and watch” policy� while 
�lastoid morphology� high proliferation and TP53 a�er-
rations are markers of aggressive disease� which will 
require intensive immunochemotherapy.
Marginal zone lymphoma (MZL): There are three 
clinicopathological entities of MZL� including extranod-
al� mucosa-associated lymphoid tissue �MALT� lympho-
ma� nodal �NMZL�� and splenic �SMZL� type. Leukemic 
presentation is more common in SMZL. The leukemic 
